Literature DB >> 25654687

[Dutch College of General Practitioners' practice guideline on 'Vaginal bleeding'].

Corlien J H de Vries1, Loes J Meijer, C A H Ineke Janssen, Jako S Burgers, Wim Opstelten.   

Abstract

The revised Dutch College of General Practitioners' practice guideline on 'Vaginal bleeding' provides recommendations for abnormal bleeding in women in the reproduction phase of life and for post-menopausal bleeding. This guideline is closely attuned to the guideline on 'Heavy menstrual bleeding' of the Dutch Society of Obstetrics and Gynaecology. Transvaginal sonography is not reliable for excluding endometrial carcinoma in women with abnormal vaginal bleeding treated with tamoxifen. The choice of medical treatment is determined in consultation with the patient. The following factors are assessed: severity and bother, long-term need for contraception, preference for cycle control, desire to have a child, pain during menstruation, comorbidity and use of medication. Treatment options are nonhormonal (NSAIDs, or tranexamic acid) or hormonal (a levonorgestrel-releasing intrauterine system, or combined oral contraceptive). In women of reproductive age, referral is indicated if medical treatment is not effective. Other indications are intracavitary abnormalities diagnosed by transvaginal sonography, tamoxifen use, persistent contact bleeding, and suspicion of coagulation disorders. Indications for referral for post-menopausal bleeding include: sonographic endometrial thickness > 4 mm, abnormal cervical cytology, tamoxifen use, irregular bleeding during use of hormone therapy for vasomotor symptoms and persistent or recurrent bleeding, regardless of endometrial thickness.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25654687

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  Predictive factors for failure of the levonorgestrel releasing intrauterine system in women with heavy menstrual bleeding.

Authors:  Pleun Beelen; Marian J van den Brink; Malou C Herman; Peggy M Geomini; Ruben G Duijnhoven; Marlies Y Bongers
Journal:  BMC Womens Health       Date:  2021-02-09       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.